Surgical Sutures Enter 23-Province Alliance Volume-Based Procurement: Polymed Medical Seizes Opportunity with Technological Edge

On April 24, 2025, the Liaoning Provincial Healthcare Security Administration issued the “Notice on Launching the Reporting of Historical Procurement Information and Projected Procurement Demand for Five Categories of Medical Consumables, Including Sutures,” thereby initiating the data collection process for these items. Medical institutions are required to report historical procurement volumes and future demand for sutures, covering both absorbable and non-absorbable types. Spanning 23 provinces and municipalities—including Tianjin, Hebei, and Shanxi—as well as the Xinjiang Production and Construction Corps, this initiative marks a critical turning point for the suture market, a sector with a market size exceeding RMB 10 billion.

According to data from the China Association of Medical Devices Industry, the domestic market size for surgical sutures exceeded RMB 8 billion in 2023. Institutions predict that the growth rate will remain at 8%–10% in 2024, with the market size approaching RMB 9 billion. For a long time, foreign brands have occupied more than 75% of the domestic suture market by leveraging technological barriers. The comprehensive rollout of centralized procurement is accelerating the reshaping of this landscape. This centralized procurement adopts a volume-for-price strategy, reducing distribution costs through large-scale purchasing and creating opportunities for Chinese-made enterprises to “overtake on the bend.”

Volume-based procurement is no longer solely focused on the lowest price; instead, it balances product quality, clinical value, and supply stability. As a leading domestic enterprise, Pulimeng Medical will seize the initiative through technological breakthroughs and comprehensive capabilities across the entire industry chain.

Among the many domestic suture brands, the Pulimeng series of specialty sutures has garnered significant attention through its innovative technologies and differentiated market strategy, breaking the monopoly held by imported brands in multiple niche segments of the specialty suture market.

Domestic Sutures Led by Pulimon Are Breaking Through Technical Barriers via Three Major Pathways:

1. Material Innovation: Various specialized suture segments, such as traditional non-absorbable sutures, absorbable sutures, and knotless barbed sutures;

2. Structural Innovation: Features a domestically exclusive 360° three-dimensional spiral barbed design for knot-free suturing, and employs 3D compression technology to provide fishbone sutures with higher fixation strength and grip;

3. Functional Upgrade: As the first company in China to fully master the technology for antimicrobial drug coating on sutures, it has received approval for the first domestically produced antimicrobial barbed suture;

Polymon has deeply cultivated the field of absorbable medical devices, launching a range of differentiated products. Its product portfolio in the specialized suture segment covers the full spectrum of clinical application needs:

China’s 14th Five-Year Plan for Medical Development explicitly supports the domestic production of high-end medical consumables. In many regions, centralized procurement programs negotiate prices separately for imported products, thereby creating market space for domestically produced alternatives and accelerating import substitution through policy incentives. According to QYResearch forecasts, the Chinese suture market is projected to reach USD 1.84 billion by 2029, with a compound annual growth rate (CAGR) of 8.6%. The “volume-for-price” mechanism of centralized procurement will drive industry consolidation, positioning leading domestic manufacturers with advantages in technology, production capacity, and distribution channels to assume a dominant role. Pulimon Medical will leverage its independently developed technological strengths, seize the opportunity presented by this centralized procurement initiative, and capture market share through differentiated pricing strategies and rapid production capacity responsiveness.

To date, Primed has been honored with titles including “National Specialized and Sophisticated ‘Little Giant’ Enterprise,” “High-Tech Enterprise,” “Provincial Specialized and Sophisticated SME,” “Jiangsu Province Potential Unicorn Enterprise,” “Jiangsu Province Gazelle Enterprise,” “Enterprise Above Designated Size,” and “Lingque Enterprise.” Furthermore, numerous hospitals have fully adopted Primed’s domestically produced suture series, achieving effective import substitution, and its products have gained widespread recognition from clinical experts.

Winning bids in centralized procurement depends not only on price but also tests a company’s capacity for large-scale supply. Pulimon Medical has achieved an annual production capacity of tens of millions of sutures through the construction of intelligent production lines, ensuring stable delivery after centralized procurement. Meanwhile, leveraging its distribution network covering more than 2,000 hospitals across China, it rapidly responds to clinical needs, forming a dual-drive model of “technology + service.”